We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Drug Targets – Products

Successful BLI

Good Data. Rich Insights. More Discoveries.

Label-free biosensor technologies have emerged as a promising approach to identify high-value hits with a strong likelihood of success as a therapeutic. Unlike traditional approaches of drug discovery, they are fast, sensitive, and come with improved success rates towards high-value drug candidates.
The Orbit Discovery logo
Product News

Orbit Discovery and Evergreen Discovery Collaborate To Discover Peptides for Targeting Radiopharmaceuticals

Evergreen Discovery and Orbit Discovery Ltd have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.
The Cardiff Oncology logo.
Product News

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase II Randomized Trial

Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.
The Carterra logo
Product News

Carterra Launches the LSAXT High-Throughput SPR Biosensor at SLAS2023

Carterra Inc. launched its latest HT-SPR instrument, the LSAXT, at the Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA.
New chief science officer, Dr. Lisa Jones
Product News

GenNext Technologies Appoints Dr. Lisa Jones of UCSD to the Role of Chief Science Officer

GenNext Technologies, Inc. has selected Dr. Lisa Jones as the company’s new chief science officer.
A closeup of many different medications
Product News

Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease

Pheno Therapeutics Limited has announced that it has entered into an exclusive worldwide license agreement with UCB.
Consistency is Key to Further Drug Discovery Research content piece image
App Note / Case Study

Consistency is Key to Further Drug Discovery Research

Energy metabolism plays a central role in a wide variety of cellular and physiological processes. Therefore, a deep understanding of how disruption to energy metabolism impacts cells can help in therapeutic drug discovery and development.
The logos of Alnylam Pharmaceuticals and Paradigm4.
Product News

Foundational Partnership With Paradigm4 Enables Alnylam Pharmaceuticals To Accelerate RNAi-Based Drug Target Discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Ubiquigent logo
Product News

Ubiquigent Appoints Dr. Sheelagh Frame, CSO, to its Board of Directors

Ubiquigent Limited today announced the appointment of Dr. Sheelagh Frame, Chief Scientific Officer, to the Company’s Board of Directors.
MACSima™ Imaging Platform – The Next Level of Context in Spatial Biology content piece image

MACSima™ Imaging Platform – The Next Level of Context in Spatial Biology

The MACSima™ Imaging Platform opens the next level of context in spatial biology, allowing fully automated imaging of 100s of protein markers on a single tissue sample. It includes a broad portfolio of pre-validated antibodies and an easy-to-use software generating ready-to-publish images and charts.